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Abstract 
Background: The invasion of the red blood cells by Plasmodium falciparum merozoites involves the interplay of 
several proteins that are also targets for vaccine development. The proteins PfRh5‑PfRipr‑PfCyRPA‑Pfp113 assemble 
into a complex at the apical end of the merozoite and are together essential for erythrocyte invasion. They have also 
been shown to induce neutralizing antibodies and appear to be less polymorphic than other invasion‑associated 
proteins, making them high priority blood‑stage vaccine candidates. Using available whole genome sequencing data 
(WGS) and new capillary sequencing data (CS), this study describes the genetic polymorphism in the Rh5 complex in 
P. falciparum isolates obtained from Kilifi, Kenya.
Methods: 162 samples collected in 2013 and 2014 were genotyped by capillary sequencing (CS) and re‑analysed 
WGS from 68 culture‑adapted P. falciparum samples obtained from a drug trial conducted from 2005 to 2007. The 
frequency of polymorphisms in the merozoite invasion proteins, PfRh5, PfRipr, PfCyRPA and PfP113 were examined 
and where possible polymorphisms co‑occurring in the same isolates.
Results: From a total 70 variants, including 2 indels, 19 SNPs [27.1%] were identified by both CS and WGS, while an 
additional 15 [21.4%] and 36 [51.4%] SNPs were identified only by either CS or WGS, respectively. All the SNPs identi‑
fied by CS were non‑synonymous, whereas WGS identified 8 synonymous and 47 non‑synonymous SNPs. CS identi‑
fied indels in repeat regions in the p113 gene in codons 275 and 859 that were not identified in the WGS data. The 
minor allele frequencies of the SNPs ranged between 0.7 and 34.9% for WGS and 1.1–29.6% for CS. Collectively, 12 
high frequency SNPs (> 5%) were identified: four in Rh5 codon 147, 148, 203 and 429, two in p113 at codons 7 and 
267 and six in Ripr codons 190, 259, 524, 985, 1003 and 1039.
Conclusion: This study reveals that the majority of the polymorphisms are rare variants and confirms a low level of 
genetic polymorphisms in all proteins within the Rh5 complex.
Keywords: Malaria, Vaccine, Rh5, CyRPA, Ripr, P113, Single nucleotide polymorphisms, Linkage disequilibrium
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco 
mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco mmons. org/ publi cdoma in/ 
zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Despite some progress over the last decade, malaria con-
tinues to be a significant global health burden with a vac-
cine deemed essential to effectively control the disease in 
high malaria transmission zones [1]. The RTS,S vaccine 
has been rolled out in three African countries [2] but 
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required. There are other candidates in the pipeline that 
show promise for incorporation into second-generation 
vaccines. One leading candidate antigen is Plasmodium 
falciparum Reticulocyte Binding homologue 5 (Rh5, 
PF3D7_0424100), which is currently advancing through 
clinical trials [4].
Rh5 is the smallest in the Reticulocyte Binding Protein 
homolog (Rh) family that includes Rh1, Rh2a, Rh2b and 
Rh4 [5, 6]. Furthermore, it is the only member of the Rh 
family without a transmembrane domain. Rh5 has been 
shown to be refractory to gene knockout experiments, 
suggesting it plays an essential role in the invasion of 
erythrocytes [5, 6] via interactions with the erythrocyte 
receptor basigin (BSG) [7]. Both monoclonal and poly-
clonal anti-Rh5 antibodies inhibit erythrocyte invasion 
of multiple parasite strains by blocking the Rh5-BSG 
interaction in  vitro [8–11]. Rh5 vaccination field trials 
in non-human primates, Aotus monkeys, demonstrated 
protection from heterologous P. falciparum challenge 
[12], while non-exposed vaccinated human volunteers 
from a phase 1a clinical trial, generated anti-Rh5 anti-
bodies that blocked merozoite invasion in  vitro [4]. 
Furthermore, while individuals from malaria endemic 
regions, who are naturally exposed to P. falciparum infec-
tions develop anti-PfRH5 antibodies at a relatively low 
prevalence, the presence of these antibodies have been 
associated with protection from symptomatic malaria in 
Papua New Guinea, and Mali [13–15]. Based on these 
findings, Rh5 has been considered as a next generation 
blood-stage malaria vaccine candidate even though it has 
low immunogenicity in natural infections.
Rh5 does not function in isolation during erythrocyte 
invasion, but acts as part of a multi-protein complex with 
Rh5 interacting protein (Ripr, PF3D7_0323400) [16], 
cysteine rich protein antigen (CyRPA, PF3D7_0423800) 
(17) and P113 (PF3D7_1420700) [18]. The Rh5-CyRPA-
Ripr complex binds better to the erythrocyte cell sur-
face than Rh5 alone [19], and interaction of Rh5 with its 
erythrocyte surface protein receptor, basigin, triggers a 
transient increase in  Ca2+ concentration and alters the 
erythrocyte cytoskeleton [20]. Rh5 undergoes proteolytic 
cleavage, resulting in fragments of approximately 18 kDa 
and 45 kDa. Rh5 binds directly to P113 (via the smaller 
Rh5 fragment, [18] and CyRPA [17], while Ripr is associ-
ated with Rh5 through its interaction with CyRPA [21]. 
Therefore, CyRPA forms the contact sites for Rh5 and 
Ripr. It has been suggested that CyRPA dissociates from 
the complex and it is excluded from the membrane dur-
ing binding to basigin. The Rh5-CyRPA-Ripr complex 
can bind to BSG without interaction with p113. However, 
P113 anchors Rh5 onto the merozoite membrane, while 
CyRPA and Ripr do not bind to erythrocytes on their 
own [16–18, 21].
Similar to Rh5, the genes encoding CyRPA and Ripr 
cannot be knocked out, suggesting that they are essential 
for parasite growth [16, 18], and conditional deletion of 
either Ripr and CyRPA results in non-invasive merozo-
ites [19]. Antibodies to all three proteins (Rh5, CyRPA 
and Ripr) of the complex can inhibit erythrocyte inva-
sion by multiple P. falciparum strains [16, 17, 22]. Fur-
thermore, antibodies to CyRPA have been reported to 
block its interaction with the Rh5/Ripr complex and the 
formation of the multi-protein complex, leading to inva-
sion inhibition [17]. In African and Papua New Guinean 
populations, P113 antibodies have been associated with 
protection against clinical malaria [13, 23]. All members 
of the Rh5 protein complex can, therefore, be considered 
potential blood-stage vaccine targets.
Polymorphisms are a particular barrier for the devel-
opment of blood-stage vaccines, as proteins that are 
exposed to the immune system during invasion are often 
very diverse, presumably the result of pressure from 
the immune system [24]. This problem of diversity has 
impeded the development of blood-stage vaccines in the 
past, with AMA1 being a prime example. Like the Rh5 
complex, AMA1 is essential for invasion, but it is highly 
polymorphic, resulting in immune responses that are 
allele-specific, a fact that may have limited the efficacy 
of previous Phase IIb trials [25]. However, Rh5, Ripr and 
CyRPA have been shown to be highly conserved [5, 22, 
26], although polymorphisms in these genes including 
p113 have not been intensively investigated. In addition, 
exploring genetic diversity in all members of the complex 
in the same infections would identify whether polymor-
phisms are associated, which would need to be taken into 
consideration during vaccine design. To explore these 
questions, we examined all the four Rh5 complex genes 
by capillary and whole genome sequencing of a cross-
sectional sample of parasites from Kilifi.
Methods
Sampling, DNA amplification and capillary sequencing
For capillary sequencing (CS), parasite DNA was 
extracted from 162 blood samples from children below 
11  years admitted and attended to at the Kilifi County 
Hospital in 2013 and 2014. The children had variable par-
asitaemia ranging from 160 to 705,600 parasites/µl, with 
a median of 7440 parasites/µl. This study was reviewed 
and approved by the Centre Scientific Committee and the 
Scientific Ethical Review Unit (SERU) of the Kenya Medi-
cal Research Institute, on SERU protocol number 3149. 
CyRPA (PF3D7_0423800), P113 (PF3D7_1420700), Ripr 
(PF3D7_0323400) and Rh5 (PF3D7_0424100) genes were 
examined. Genomic DNA was previously extracted from 
packed frozen erythrocytes using the QIAcube (Qiagen), 
according to the manufacturer’s instructions (QIAGEN, 
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UK). All four genes were amplified using High Fidel-
ity Taq polymerase (Roche) (primers used are shown in 
Additional file 1: Table S1). PCR products were visualized 
on 1% agarose gels prior to sequencing to confirm their 
expected band size (Additional file 2: Table S2). Purified 
amplicons were directly sequenced using the PCR prim-
ers and additional sequencing primers (Additional file 1: 
Table  1), BigDye terminator chemistry v3.1 (Applied 
Biosystems, UK) and an ABI 3730xl capillary sequencer 
(Applied Biosystems, UK). The raw sequences for each 
targeted gene were assembled, edited, and aligned 
using SeqMan and MegAlign software (Lasergene 12; 
DNASTAR). All singleton SNP sites were confirmed by 
independent reamplification and resequencing of the rel-
evant samples. Positions of the sequences that showed 
mixed or superimposed nucleotides (peak within a peak) 
were marked with IUPAC ambiguity codes and consider 
as a mixed infection and excluded from the SNP and hap-
lotype frequencies.
Sampling, DNA preparation and whole genome 
sequencing
For whole genome sequencing, parasite DNA was pre-
viously extracted from 68 blood samples obtained from 
children recruited into an artemisinin-based combina-
tion therapy (ACT) drug trial of dihydroartemisinin-
piperaquine and artemether-lumefantrine conducted 
in Pingilikani dispensary, Kilifi from 2005 to 2007 [27]. 
Additionally, some samples were from patients admit-
ted to the Kilifi County Hospital with severe malaria. 
All studies obtained clearance from the Kenya Medical 
Research Institute (KEMRI) Ethical Review Committee 
under protocol numbers SSC 945. Samples were cryo-
preserved in glycerolyte and later adapted to culture for 
about 2  months for chemosensitivity testing [28]. DNA 
was also extracted and contributed to MalariaGEN for 
whole genome sequencing (WGS) and genotyping on an 
Illumina Genome Analyzer to a read depth of approxi-
mately 98 × in genotyped sites, and reads of length 
37–76 base pairs as described in Wendler et al. [29]. The 
genotype data generated from the sequence reads were 
obtained from the MalariaGEN P. falciparum Commu-
nity Project [30]. The selected SNPs were from those 
identified in release 6.0.
Read mapping and coverage analysis
A VCF file containing 68 samples obtained from Kilifi, 
Kenya, were used as the input file in the downstream 
analysis. Using VCFtools (v. 0.1.13) a targeted analysis 
of four genes: Rh5, Ripr, CyRPA and P113 was filtered, 
by using a bed file containing the chromosome numbers 
and genomic positions, to generate one VCF file. Using 
PLINK [31], the VCF files were then examined to obtain 
a list of high quality SNPs, by excluding variants based on 
the following criteria: a) the SNPs with the ‘FAIL’ filter; b) 
non-coding SNPs; c) SNPs that have extremely low sup-
port (< 10 reads in one sample); and d) variants that did 
not pass the minor allele threshold of < 0.5% based on the 
number of reads obtained per variant.
Global malariaGEN data retrieval and analysis
To further validate the SNPs, we identified through CS 
and WGS, data from the MalariaGEN Plasmodium fal-
ciparum community project version 4.0 was used. This 
data was generated through an analysis of 3488 P. fal-
ciparum samples collected at 43 different locations in 
West Africa (WAF), Central Africa (CAF), East Africa 
(EAF), South Asia (SAS), West South East Asia (WSEA), 
East South East Asia (ESEA), Oceanic (OCE) and South 
America (SAM). A total 930,000 exonic SNPs and their 
frequencies were obtained. The method used to gener-
ate the data are described in Amato et al. [32]. The dplyr 
v1.0.0 package [33] in R v4.0.2 [34] was used to filter 
our four genes of interest based on their unique Gene 
IDs: CyRPA (PF3D7_0423800), P113 (PF3D7_1420700), 
Ripr (PF3D7_0323400) and Rh5 (PF3D7_0424100). The 
pool of SNPs identified were filtered to obtain their 
frequencies.
Population genetics statistical tests
The allele frequency distribution indices, Tajima’s D and 
Fu and Li’s D* and F*, were computed using DnaSP v5.10 
software [35] for the capillary sequence data. Tajima’s 
D computed the differences between two estimators of 
theta, based on the number of segregating sites and the 
average number of nucleotide differences [36]. Fu and 
Li’s D* test statistic calculated the differences between 
the observed number of singletons (mutations appearing 
only once among the sequences), and the total number 
of mutations [37] Fu and Li’s F* test statistic considered 
the differences between the number of singletons and the 
average number of nucleotide differences between pairs 
of sequences [37]. For the p values DnaSP calculated the 
confidence limits of D (two-tailed test) and assumed that 
the statistic follows a beta distribution.
Linkage disequilibrium analysis
For each of the four genes obtained from the whole 
genome data, the minor and major allele frequencies of 
all the SNPs were computed using PLINK. Only SNPs 
with a > 5% minor allele frequency were included in 
the analysis. The extent of linkage disequilibrium (LD) 
between pairs of SNPs in Rh5, Ripr, CyRPA and P113 was 
determined within and between genes using R v3.6.0. The 
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statistical significance of LD was tested, at the 5% level, 
using χ2 tests.
Rh5‑CyRPA‑Ripr complex protein structures
The cryo-electron microscopy structure of Rh5-CyRPA-
Ripr (PDB ID: 6MPV) was downloaded from the Pro-
tein Data Bank (http:// www. rcsb. org/). Wong et  al. [21] 
reported only the structures for Rh5 (residues 175–243 
and 298–504) and CyRPA (residues 31–122, 126–242, 
254–319 and 323–362) as the Ripr model could not be 
built de novo owing to resolution of the electron den-
sity map. However, based on the alpha helix structures 
described we use this to obtain a partial structure for 
Ripr. Using the generated dataset in this study, the Rh5 
and CyRPA polymorphic sites were mapped onto their 
protein structures in Pymol (The PyMOL Molecular 
Graphics System, Version 2.2.0, Schrödinger, LLC), to 
determine the location of the polymorphisms in the 
three-dimensional conformation of the complex and 
whether the polymorphic sites were found in the binding 
regions of each protein.
Results
Population genetics summary statistics
All genes had a negative summary statistic, although 
only P113 and Ripr reached significance with a negative 
value for either the Tajima’s D or Fu & Li D* & F* or both 
statistics (Tables  1 and 2). P113 yielded values of -2.2, 
-3.2 and -3.4, respectively for CS data, with comparable 
results observed using the whole genome data of -2, -3.2 
and -3.4. A similar observation was made with Ripr with 
the capillary data giving only significant values of − 2.5, 
and − 2.5 for the Fu & Li D* and F*, respectively, while 
the whole genome data yielded results of -2.8 and -2.9, 
respectively.
Genetic diversity in the Rh5 complex genes identified 
using capillary sequencing data
Capillary sequencing data was attempted from 162 
samples taken from children admitted to Kilifi Hospi-
tal. Data on all four genes was not obtained by capillary 
sequencing for any single sample, but data was obtained 
for multiple pairs of genes from individual isolates: 
p113 & CyRPA, p113 & Ripr and Rh5 & CyRPA. Capil-
lary sequence data for both p113 & Rh5 and CyRPA & 
Ripr gene pairs were obtained in less than 20 samples, 
while 46 samples yielded sequence data for P113 and 
CyRPA (Table 3). No synonymous SNPs were detected, 
while 32 non-synonymous (ns) SNPS were identified in 
total. CyRPA, p113, Rh5 and Ripr sequences contained 
4, 10, 6 and 12 SNPs, respectively (Table 4). Most SNPs 
Table 1 Capillary sequence population genetics summary statistics
n- number of sequences, S- number of segregating sites, Sn- number of singletons, *p < 0.05, **P < 0.01, #p < 0.02
Gene Size (bp) n S Sn π Tajima’s D Fu & Li D* Fu & Li F*
CyRPA 5’ 586 45 1 1 0.00018 − 1.113 − 1.809 − 1.861
CyRPA 3’ 225 87 4 2 0.00061 − 1.682 − 1.419 − 1.765
P113 2469 91 13 8 0.00019 − 2.22** − 3.16* ‑− 3.36#
Rh5 1105 50 7 2 0.0015 0.093 − 0.316 − 0.217
Ripr 1434 66 8 5 0.00056 − 1.349 − 2.479* − 2.483*
Table 2 Whole genome sequence population genetics summary statistics
n- number of sequences, S- number of segregating sites, Sn- number of singletons, *p < 0.05, **p < 0.02
Gene n S Sn π Tajima’s D Fu and Li’s D* Fu and Li’s F*
CyRPA 68 5 2 0.00211 − 1.552 − 0.976 − 1.364
P113 68 12 8 0.00195 − 2.043* − 3.240* − 3.350**
Rh5 68 10 4 0.01171 − 0.376 − 1.272 − 1.092
Ripr 68 20 12 0.00956 − 1.648 − 2.847* − 2.871*
Table 3 The number of samples from which capillary sequence 
data was obtained for each gene combination
Genes Samples 
(n = 162)
p113 + CyRPA 46
P113 + RIPR 25
Rh5 + CyRPA 24
p113 + Rh5 18
CyRPA + Ripr 14
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were found in multiple isolates  (Additional file  3), 
although 3 SNPs in CyRPA and Ripr and 5 in p113 were 
singletons (found in only a single isolate). Indels were 
only found in p113, with variation in repeat regions at 
codon 275 with asparagine (N) (ranging from 3 to 9 N) 
and at codon 859 with glutamic acid (E) (ranging from 
2 to 3E). The CyRPA analysis was conducted in two 
fragments from the N and C-terminal ends. The N-ter-
minal end fragment, codons 1 to 170, contained only 
one non-synonymous SNP, at codon 165 and found 
in only a single infection, while the C-terminal end 
though shorter in comparison contained three poly-
morphic sites. 
Table 4 The frequency of variants in the Rh5 complex genes identified by CS and WGS
CyRPA: 12 SNPs, p113: 27 SNPs, Ripr: 25 SNPs and Rh5: 11 SNPs. SNPs that were identified by either CS or WGS and present in the global MalariaGEN dataset are 
indicated by an asterix* and singleton SNPs are indicated by a hash #
Gene Position S/NS/Indel Frequency Gene Position S/NS/Indel Frequency
CS WGS CS WGS
Rh5 Rh5_42 NS 2.3# 0 CyRPA CyRPA_101 S 0 4.1
Rh5_147* NS 20.5 22.6 CyRPA_160* NS 0 0.7#
Rh5_148* NS 20.5 22.6 CyRPA_165* NS 2.2 0.7#
Rh5_203* NS 13.6 10.3 CyRPA_229 NS 0 1.4#
Rh5_365* NS 0 0.7# CyRPA_235* NS 0 0.7
Rh5_371* NS 0 4.1 CyRPA_236 NS 0 3.4#
Rh5_389* NS 0 0.7# CyRPA_270* NS 0 2.8
Rh5_407* NS 0 0.7# CyRPA_271* NS 2.3 0
Rh5_410* NS 4.6 3.4 CyRPA_292* NS 1.2# 0
Rh5_429* NS 29.6 34.9 CyRPA_302* NS 1.2# 2.1
Rh5_439*# NS 0 1.4 CyRPA_17* NS 0 0.7#
P113 p113_5* NS 0 1.4 CyRPA_19* NS 0 0.7#
p113_7* S 0 5.1# Ripr RIPR_3 NS 0 1.4
p113_234* NS 1.1 1.4 RIPR_66* NS 0 0.7#
p113_267* NS 4.4 7.5 RIPR_119 NS 0 0.7#
p113_275_3N Indel 2.2 0 RIPR_190* NS 7.6 10.3
p113_275_6N Indel 72.5 0 RIPR_215* NS 0 2.7
p113_275_7N Indel 1.1 0 RIPR_220 NS 1.5 0
p113_275_8N Indel 23.1 0 RIPR_226* NS 3.0 0
p113_275_9N Indel 1.1 0 RIPR_228* S 0 0.7#
p113_310 NS 3.3 3.4 RIPR_255 NS 1.5 2.8
p113_330* NS 1.1# 0 RIPR_259* NS 27.3 23.6
p113_345* S 0 1.4# RIPR_327* NS 4.6 3.4
p113_381* S 0 0.7# RIPR_429 NS 0 0.7#
p113_421* NS 1.1# 0 RIPR_436* NS 0 0.7#
p113_453* S 0 1.4# RIPR_438* NS 0 0.7#
p113_478 NS 0 0.7# RIPR_524* NS 12.1 0.7#
p113_485* NS 0 1.4# RIPR_564 NS 1.5# 0
p113_620 NS 3.3 0 RIPR_587 NS 1.5 0
p113_713* NS 2.2 0 RIPR_744* S 0 0.7#
p113_716 NS 2.2# 0 RIPR_843 NS 0 1.4
p113_750 S 0 0.7# RIPR_858* NS 0 0.7#
p113_758* NS 1.1 2.1 RIPR_883* NS 0 0.7#
p113_849 NS 1.1# 0 RIPR_985* NS 12 8.9
p113_859_2E Indel 3.3 0 RIPR_995* NS 0 1.4#
p113_859_3E Indel 96.7 0 RIPR_1003* NS 15.4 10.3
p113_912* NS 0 1.4# RIPR_1039* NS 12 2.7
p113_935* NS 0 0.7#
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Genetic diversity in the Rh5 complex genes identified 
using whole genome sequencing data
Whole genome sequencing (WGS) SNP data for all the 
four genes were obtained from 68 independent sam-
ples from a previous drug trial (Additional File  4). A 
total of 55 SNPs were identified within the Rh5 gene 
complex: 10 in CyRPA, 14 in P113, 21 in Ripr and 10 
in Rh5 as shown in Table 2. There was a total of eight 
synonymous polymorphisms, 1 in CyRPA, 5 in p113 
and 2 in Ripr and forty-seven ns polymorphisms with 
CyRPA, p113, Rh5 and Ripr containing 9, 9, 10 and 19, 
respectively (Table  4). Seven of the eight synonymous 
SNPs (unique to the WGS data) were singletons except 
CyRPA codon 101 whose frequency was > 5%. Given 
that our WGS data only contained SNP data, we did 
not explore the repeat sequences identified by CS in the 
p113 gene.
Comparison of variants identified by CS and WGS 
with the global MalariaGEN data
In keeping with previous studies, the majority of vari-
ants in the Rh5 complex genes were rare, which meant 
that most were unique to each sequencing method, and 
very few SNPs were identified by both methods. In Rh5, 
CyRPA, p113 and Ripr we observed 5, 1, 4, and 8 SNPs, 
respectively, that were identified by both methods. The 
MalariaGEN global variation dataset was screened to 
explore whether SNPs were missed, perhaps due to meth-
odological differences. This analysis established that all 
common variants identified in our analysis (MAF > 5%) 
for Rh5, P113 and Ripr were also found in the global 
MalariaGEN dataset, arguing against any systematic 
missing SNP identification issues. In addition, more than 
two thirds of the rare variant SNPs were identified in 
these samples had also been identified previously in the 
global MalariaGEN data, giving us confidence in the pol-
ymorphisms identified in this study using CS and WGS. 
Combining our data with global MalariaGEN data con-
firmed that the majority of variants in the genes encoding 
the Rh5 complex are rare mutations (Table 4).
Linkage disequilibrium analysis
The LD within and between genes was examined in SNPs 
with minor allele frequencies of > 5%. 6 SNPs and 4 SNPs 
were identified before and after Bonferroni correction, 
respectively. The 4 SNPs in LD after Bonferroni correc-
tion were within Rh5 and Ripr. In Rh5, LD was observed 
in codons 147 and 148, p < 0.0001 and in Ripr, LD was 
observed between codons 985 and 1003 p-value of < 0.01. 
Due to the high number of rare variant SNPs in CyRPA, 
none were included in the LD analysis.
Visualizing mutations on the protein complex structure
Mutations within known protein interacting regions 
were mapped onto published structures for the Rh5 pro-
tein complex. The structure of the CyRPA-Rh5 interac-
tion has been published [21] and the Basigin structure 
was added to show its interaction with Rh5. The crys-
tal structure of Ripr and P113 has not been solved and 
hence their polymorphic residues in these proteins could 
not be mapped. Rh5 interacts with BSG through an α-2, 
α-4 and a disulphide loop region [38]. This Rh5-basigin 
interacting region includes Rh5 codon 203, a SNP that 
was identified at a frequency of > 5% in both the CS and 
WGS. We mapped back the identified rare variants to the 
protein structures (Fig. 1), and only two SNPs in CyRPA 
(codon 292 identified by CS and codon 302 identified 
by both CS and WGS, both at MAF < 5%) were located 
within the CyRPA-Ripr interacting region [21]. The Ripr 
α- helix, Fig. 1, corresponding to amino acid residues 196 
– 211, interacts with blade 6 of the CyRPA β-propeller, 
amino acids 281 to 311 [21]. All the SNPs identified by 
CS and WGS in Ripr fall outside the Ripr α- helix, where 
the structure has not been solved.
Discussion
The Rh5 complex is a relatively conserved set of proteins 
with few polymorphisms. They are not highly immu-
nogenic, as previously shown [15, 23]. The negative 
population genetics summary statistics do not indicate 
balancing selection and show an excess of rare variants. 
This is consistent with an analysis of genomes from P. 
Fig. 1 SNPs within protein–protein interacting regions of BSG, Rh5, 
CyRPA and Ripr. The interacting crystal structures of BSG (grey), Rh5 
(yellow), CyRPA (green) and Ripr alpha helix (black) showing SNPs 
that fall within protein–protein interacting regions. In red, are the 
polymorphic residues identified in codon C203Y of Rh5 and codon 
D302E and F292V of CYPRA. Of the SNPs identified in the Rh5‑CyRPA 
structure only the high frequency Rh5 codon 203 falls in the region 
that interacts with BSG. The singleton SNPs in codon F292V and 
D302E denoted by a hash#, lie within the region that interacts with 
Ripr. Apart from the short α‑helical structure, the Ripr structure was 
not available on Protein Data Bank
Page 7 of 10Ndwiga et al. Malar J          (2021) 20:278  
falciparum populations in Africa, which revealed that 
the majority of genes were associated with a negative 
Tajima’s D value. Therefore, suggesting there was a his-
torical parasite population expansion in Africa [39–41]. 
The genes with a significant, negative population genet-
ics summary statistics, indicate that these genes have a 
limited potential to retain mutations, in particular p113 
and Ripr, which may be due to the parasite’s need to 
preserve their function. These proteins are involved in a 
critical step during the invasion of erythrocytes and this 
polymorphism data reinforces the fact that they are likely 
to make good vaccine candidates to inhibit invasion and 
prevent disease [42].
Sequence data was obtained using two different meth-
ods and resulted in the identification of more SNPs using 
whole genome sequencing (WGS) analysis than Capil-
lary Sequencing (CS), but there are pros and cons to both 
approaches. In CS, each read is accompanied by a long 
(on average 500 bp) chromatogram, which makes it easy 
to assemble and align to a reference genome in order to 
manually identify variants, but the process as a whole 
is low-throughput. In WGS, millions of short reads are 
produced with each read being accompanied by a qual-
ity score. It is thus not feasible to manually check the 
quality of each nucleotide and quality score cut-offs are 
set in the bioinformatic pipelines to confidently call a 
nucleotide. This presents a challenge in identifying indels 
within repeat regions—because the assembly and align-
ment of these regions to reference genomes is based on 
short reads, confidence is often low in these regions, 
making it difficult to unambiguously determine the num-
bers of repeat nucleotides [43]. However, the ability of 
WGS to generate large numbers of reads and identify 
SNPs in mixed infections allows more robust identifi-
cation of SNPs, and it is therefore more reliable in the 
detection of low frequency variants as compared to CS. 
The Global MalariaGEN dataset was used to confirm 
the SNPs identified by the two methods. A large major-
ity (> 65%) of the SNPs described in these samples have 
also been described in other locations within the Global 
MalariaGEN data, providing confidence both the high 
frequency and rare SNPs detected. Furthermore, most 
SNPs that were only identified by one method were rare 
variants, making it not surprising that there were missed 
by the other method, as the two methods were applied 
to different sample sets. If a rare variant is only present 
in few infections, the chances of such infections being 
present in the samples used for both methods is signifi-
cantly reduced. It is also important to note that the sam-
ples utilized in WGS and CS, were obtained in different 
time points, which are 2005–2007 and 2013, respectively. 
In addition, the parasites used in obtaining the whole 
genome sequence data underwent culture-adaptation 
prior to sequencing, therefore the quality of DNA is 
expected to be higher in culture adapted parasites due to 
less contamination by host DNA. Cultured P. falciparum 
parasites have been known to differ significantly from 
source populations due to adaptation to environments 
that exclude the host immune responses [44]. There are 
therefore multiple reasons that could explain why differ-
ent SNPs were identified in the two different approaches.
The majority of the polymorphisms in this com-
plex or merozoite invasion antigens were rare, which is 
in contrast to previous findings from surface exposed 
and abundant merozoite antigens such as apical mem-
brane antigen 1 (AMA1) [45], merozoite surface pro-
tein 1 (MSP1) [45], MSP3 [46] and erythrocyte binding 
antigen-175 (EBA175) [47], which are under balancing 
selection and exhibit allele-specific immunity in vaccine 
trials. In a recent study of samples from Nigeria, only 5 
non-synonymous SNPs were identified in Rh5: K62R, 
T81Q, P197S, C203Y and H240R [48], of which only the 
C203Y mutation was identified in our study, while codon 
197 was described in the global MalariaGEN dataset, 
codons 62, 81 and 240 are potentially rare variant sites. 
Of note, the high frequency sites of codons 147 and 148 
in this study were not identified in the Nigerian study. 
However these aforementioned sites were described 
alongside codons S197Y, C203Y and I410M as common 
variants occurring at a frequency above 10% globally [9]. 
However, the I410M mutation was a rare variant (< 5%) in 
our population. It appears that apart from a few high fre-
quency sites that have been consistently identified in pre-
vious studies and in our study, most mutations in Rh5 are 
rare variants. Rh5 antibodies primarily inhibit parasite 
invasion by disrupting the Rh5-basigin interaction [38].
This study identified only one Rh5 mutation C203Y 
at the Rh5-Basigin interface. It has been shown that 
the Rh5 protein variant with the 203Y mutant binds to 
recombinant basigin with the same affinity as the Rh5 
C203 wild type [49]. It is therefore likely that other rare 
Rh5 mutations that cluster around the basigin interface 
will prevent binding of monoclonal antibodies. Based on 
monoclonal antibody data [50], these SNPs fall within the 
region of a large number of mouse and human antibod-
ies that have shown neutralising activity within codons 
26–352, suggesting that the rare variants identified in this 
study will potentially have an effect on antibody bind-
ing epitopes [9, 11, 17]. A similar scenario is observed 
with CyRPA, where only 1 SNP (R339S) was identified 
from a sample of 12 geographically distinct laboratory 
isolates and 6 field isolates [22] and again this SNP was 
not identified in the Kilifi samples. An analysis of 80 Ripr 
sequences from Uganda, identified 16 SNPs of which 
two codons (190 and 259) were > 5% in frequency. This 
study only found 9 of the 16 Ugandan SNPs and the SNPs 
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unique to the Ugandan population were all singletons 
[26]. Moreover, Ntege et  al. [26] also showed, like this 
study, a negative and significant Tajima’s D index. These 
studies further indicate that these genes tend to contain 
rare variants. The common variants identified across all 
the study sites should be considered in future studies to 
determine if they influence the functionality of the multi-
ple protein complex.
The low immunogenicity of Rh5 complex members in 
field studies [12, 15, 22] would suggest limited immune 
pressure on these antigens and thus a limited need for 
the parasite to acquire mutations to escape host immune 
responses. This could explain the limited high frequency 
polymorphisms and the excess of rare variants observed. 
Slightly higher responses have been observed for p113 in 
individuals in Kilifi, when compared to Rh5 [23]. Beside 
the role of p113 in invasion by binding to the Rh5 N-ter-
minal region [18], p113 is also thought to be involved in 
translocation through association with the Plasmodium 
translocon of exported proteins (PTEX), which is known 
to be a mechanism of immune evasion [51]. Further 
investigation is required to understand the effect of P113 
polymorphisms on translocation. While there is lim-
ited literature on natural immune responses to Ripr, we 
anticipate similar findings as seen with CyRPA and Rh5, 
given that Ripr is part of the same Rh5 protein complex. 
The Rh5 protein complex is hidden within the merozoite 
apical end during tight junction formation. It is, there-
fore, likely that these proteins are rarely exposed to the 
immune system and thus their immunogenicity in indi-
viduals living in malaria endemic regions is low. Their 
role in tight junction formation indicates an important 
function in merozoite invasion, which has been deter-
mined by an inability to genetically disrupt all of the 4 
genes and by the protective immune responses generated 
by antigens like Rh5 and p113 [50].
Most of the observed SNPs were not in statistically 
significant LD with the exception of codons 147 and 148 
for Rh5 and 985 and 1003 in CyRPA, which are 3 bp and 
54 bp apart respectively. The limited LD is likely due to 
a combination of the fact that most of the SNPs are rare 
variants and therefore occur at a low frequency, and the 
limited sample size in this study. Rh5 codons, 147 and 
148 are included in the protein structure [38] on the 
upstream of the alpha helix, while the structure of Ripr 
has not been fully resolved. Since they are high frequency 
SNPs, they may be involved in processes other than pro-
tein-proteins interactions, but these are yet to be deter-
mined. Only one high frequency SNP at Rh5 codon 203, 
identified by both CS and WGS, has been shown to be 
localized in the Rh5-basigin interface [38].
The development of new tools and adaptation of exist-
ing tools for use in malaria elimination and eradication 
remains a priority, and deeper understanding of 
polymorphism(s) in vaccine candidate genes is particu-
larly important. This study highlights pros and cons to 
both CS and WGS approaches to identifying vaccine-
relevant polymorphisms. The ideal molecular tool should 
be able to provide quality and high-throughput sequence 
reads capable of detecting low frequency variants includ-
ing indels. One such approach would be amplicon deep 
sequencing, where longer fragment amplicons can be 
generated and sequenced using an NGS platform, focus-
sing analysis on the regions of interest rather than the 
whole genome, but producing deeper and higher qual-
ity data than CS. Low frequency mutations should be 
assessed by functional assays to ascertain their biological 
and immunological relevance. One of the main obstacles 
in the development of effective vaccines for malaria is the 
occurrence of polymorphisms on candidate vaccine tar-
gets that result in strain-specific immunity. Among the 
members of the Rh5 complex, Rh5 is the most advanced 
in vaccine development. The identification of a limited 
number of high frequency polymorphisms on Rh5 shows 
promising prospects of Rh5 based vaccines in this region, 
but it is still possible that low frequency variants may 
lead to immune evasion—this needs to be systematically 
investigated.
Conclusion
One gene does not appear to conceal the other genes in 
the complex, by being more polymorphic and acting as 
a decoy to direct the immune pressure away from the 
rest of the genes in the complex. Thus, the limited poly-
morphisms are potentially a result of their hidden loca-
tion in the apical end of the merozoite and their limited 
exposure to host immune responses. Due to the minimal 
acquisition of mutations, Rh5, CyRPA, Ripr and P113 
proteins are potentially a good next-generation multi-
antigen vaccine formulation.
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